Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423986 | 1.00 | HTR1A (0.31) | HTR1AMGLLMOGAT2PARP1DRD2 | |
| SCHEMBL26307799 | 0.89 | PARP1 (0.31) | HTR1APARP1DRD2ADRA1DADRA1A | |
| SCHEMBL30424205 | 0.85 | MOGAT2 (0.32) | HTR1AMOGAT2 | |
| SCHEMBL24253528 | 0.85 | MOGAT2 (0.32) | HTR1AMOGAT2 | |
| SCHEMBL30424472 | 0.83 | SLC34A1 (0.34) | MOGAT2 | |
| SCHEMBL24253938 | 0.83 | SLC34A1 (0.34) | MOGAT2 | |
| SCHEMBL24253900 | 0.82 | PDE10A (0.32) | MGLLMOGAT2 | |
| SCHEMBL24253731 | 0.82 | MOGAT2 (0.33) | MGLLMOGAT2 | |
| SCHEMBL30423610 | 0.81 | HCRTR1 (0.31) | — | |
| SCHEMBL24253628 | 0.81 | HCRTR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| CN-116157404-A | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | 诺华股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | HTR1A 1336/4885MGLL 4200/4885MOGAT2 4470/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | HTR1A 1336/4885MGLL 4200/4885MOGAT2 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.